

#6
1624 6/28/02
SN

Case S03285

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Ish K. Khanna, et al.

GROUP ART UNIT:

SERIAL NO.:

09/942,174 ✓

EXAMINER:

FILED:

August 29, 2001 ✓

DATE: June 14, 2002

TITLE:

BICYCLIC $\alpha\beta_3$ ANTAGONISTS ✓

RECEIVED
JUN 9 5 2002
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks
Washington, D.C. 20231
Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

These newly cited documents are as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Rachel A. Polster ✓

Rachel A. Polster
Registration No. 47,004
(314) 694-7354 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
800 North Lindbergh Boulevard
St. Louis, Missouri 63167

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Ish K. Khanna, et al.

Docket No.

S03285

Serial No.

09/942,174

Filing Date


August 29, 2001

Examiner

TBA

Group Art Unit

TBA

Invention: **ORFIC CLIC ALPHA V BETA 3 ANTAGONISTS**

I hereby certify that this Supplemental Information Disclosure Statement
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The
Assistant Commissioner for Patents, Washington, D.C. 20231 on June 14, 2002
(Date)

Edwina Ragan

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.